Samer Khouri, MD
Cardiovascular Disease · Toledo, OHNPI 1285628313
Payments from drug & device makers
What this record shows
Abbott accounts for 78.4% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $1,842, 9.1 times the $201 reported in 2019.
Across 46 payments — averaging $91.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Musculoskeletal Transplant Foundation Inc.$182
- Boston Scientific$181
- Novo Nordisk$115
- Heartflow, Inc.$75
- Lifenet Health$56
- plus $295 from 9 others
Across 79 payments — averaging $3890.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$261K
- Boehringer Ingelheim International GmbH$27K
- Boehringer Ingelheim Pharma GmbH & Co.kg$11K
- United Therapeutics Corporation$8K
- Actelion Pharmaceuticals, Ltd$700
- Actelion Pharmaceuticals US, Inc.$235
What the payments were for
- Travel & lodging$2,21753%
- Food & beverage$1,97447%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 27 | $3,286 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $182 |
| Boston Scientific | 2 | $181 |
| Novo Nordisk | 1 | $115 |
| Heartflow, Inc. | 2 | $75 |
| Lifenet Health | 1 | $56 |
| Johnson & Johnson | 1 | $54 |
| Inari Medical, Inc. | 2 | $47 |
| Novartis | 2 | $41 |
| Bracco Diagnostics Inc. | 1 | $32 |
| Pfizer | 2 | $31 |
| United Therapeutics Corporation | 1 | $28 |
| Medtronic | 1 | $27 |
| GE HealthCare | 1 | $19 |
| Impulse Dynamics (USA) Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRICLIP$1,283
- MitraClip$1,222
- GENERAL PAIN MANAGEMENT$140
- CardioMEMS HF System$129
- AMPLATZER AMULET$120
- HeartMate 3 Left Ventricular Assist Device$115
- Wegovy$115
How this compares
$4,191 in reported general payments places this provider in the 70th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 20 | $257,961 |
| UptraviSelexipag | 13 | $170,087 |
| AdempasRiociguat | 11 | $159,570 |
| EliquisApixaban | 139 | $132,588 |
| Ambrisentan | 24 | $29,879 |
| FarxigaDapagliflozin Propanediol | 35 | $29,058 |
| EntrestoSacubitril/Valsartan | 34 | $27,950 |
| XareltoRivaroxaban | 19 | $25,741 |
| Tadalafil | 26 | $18,191 |
| Bosentan | 11 | $13,772 |
| Praluent PenAlirocumab | 22 | $10,758 |
| Enoxaparin Sodium | 24 | $3,412 |
| Atorvastatin Calcium | 221 | $2,865 |
| Metoprolol Succinate | 221 | $2,844 |
| Bumetanide | 49 | $2,216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $31 | $132,588139 claims |
| NovartisEntresto | $41 | $27,95034 claims |
| Johnson & JohnsonXarelto | $54 | $25,74119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Toledo
- Rajendra KattarToledo$37K
- Guilherme AttizzaniCleveland$1.3M
- Gregory LamCircleville$428K
- Emil HayekHudson$379K
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Kamal ShemisaCincinnati$314K
- Mehdi ShishehborElyria$237K
- Abdu HawwaGarfield Hts$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.